Johnson & Johnson has reported late‑breaking phase 2 results showing that nipocalimab met the primary endpoint of reducing ...
Deep Science Ventures (DSV) and Medicines Discovery Catapult (MDC) have formed a strategic partnership to tackle one of ...
JJP Biologics has reported positive interim findings from its ongoing phase 1b study of nebaprubart (JJP‑1212) in patients with linear IgA disease, a rare autoantibody‑driven blistering disorder with ...
Aragen has completed the technology transfer and first commercial-scale GMP manufacturing runs for Renaissance Pharma’s lead ...
This issue reminds us that humankind remains the enduring question, and diversity in clinical trials is the answer (even if ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results